| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
MDA19 has an approximately 70-fold higher affinity for the human CB1 receptor and a 4-fold higher affinity for the human CB(2) receptor compared to the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM). periods. K(i) = 16.3 +/- 2.1 vs. 1130 +/- 574 nM for rat CB2 vs. rat CB1 receptor. MDA19 functioned as an agonist at rat CB1 receptors, human CB1 and CB2 receptors, and inversely as an agonist at rat CB2 receptors in guanosine triphosphate (GTP)gamma[(35)S] functional tests. In the 3',5'-cyclic adenosine monophosphate (cAMP) experiment, MDA19 functioned as an agonist at the rat CB1 receptor but did not exhibit any functional activity at the rat CB(2) receptor. In the test for extracellular signal-regulated kinase 1 and 2.
|
|---|---|
| ln Vivo |
Rat CB2 receptors are agonistically activated by MDA19. MDA19, but not CB2(-/-) mice, dose-dependently reduces the tactile allodynia caused by spinal nerve ligation or paclitaxel in rats and CB2(+/+) mice. This suggests that the CB2 receptor mediates the role of MDA19. In rats, MDA19 has no effect on locomotor activity.
|
| References |
|
| Molecular Formula |
C21H23N3O2
|
|---|---|
| Molecular Weight |
349.434
|
| Exact Mass |
349.179
|
| CAS # |
1048973-47-2
|
| PubChem CID |
135743701
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.607
|
| LogP |
4.99
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
26
|
| Complexity |
476
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ICNRTDOKKSWDRL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14,26H,2-4,10,15H2,1H3
|
| Chemical Name |
N-(1-hexyl-2-hydroxyindol-3-yl)iminobenzamide
|
| Synonyms |
MDA19; MDA 19; MDA-19
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~14.29 mg/mL (~40.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.43 mg/mL (4.09 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8618 mL | 14.3090 mL | 28.6180 mL | |
| 5 mM | 0.5724 mL | 2.8618 mL | 5.7236 mL | |
| 10 mM | 0.2862 mL | 1.4309 mL | 2.8618 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
